What`s New in Acute Graft-versus-Host Disease?
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Aromatase Inhibitors Favored as Adjuvant ET in HR+/HER2+ Early Breast Cancer
2
ASCENT-07: Sacituzumab PFS Not Significant vs Chemo in HR+/HER2- BC
3
Off-the-Shelf In Vivo BCMA CAR T KLN-1010 Yields Deep R/R Myeloma Responses
4
Giredestrant Improves IDFS vs SOC in ER+/HER2– Early Breast Cancer
5
